Aquestive raises $4.8M via warrant exercise; issues new warrants at $2.60 strike, expiring 2029

Aquestive Therapeutics, Inc.

Exercise of 5M existing warrants at $0.96 yields ~$4.8M gross proceeds to Aquestive.
Issued new warrants to purchase up to 2.75M shares at $2.60, expiring Feb 2, 2029.
Company agreed to 30-day lock-up on further securities offerings and no variable-rate transactions.
Beneficial ownership limitation on new warrants set at 4.99% (option to increase to 9.99%).
Company to file resale registration statement for new warrant shares within 60 days.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aquestive Therapeutics, Inc. entered into Letter Agreement valued at approximately $4,800,000.00 (effective 2023-08-01).

Action: entry
Agreement: equity purchase
Value: approximately $4,800,000.00
Effective: 2023-08-01

Exact text from the filing

On August 1, 2023, the Company entered into an Inducement Offer to Exercise Common Stock Purchase Warrants letter agreement (the “Letter Agreement”) with the holder (the “Exercising Holder”) of 5,000,000 of the remaining Common Stock Warrants (the “Existing Warrants”).

View on SEC.gov

Browse all material agreements →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-026584

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.